<DOC>
	<DOC>NCT01974271</DOC>
	<brief_summary>This prospective, multicenter, observational study will evaluate the impact of comorbidities on hemoglobin stability in chronic kidney disease patients on dialysis treated with Mircera (methoxy polyethylene glycol-epoetin beta). Eligible patients will be followed for 6 months of treatment.</brief_summary>
	<brief_title>An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Chronic kidney disease patients on hemodialysis or hemodiafiltration for at least 3 months Previously treated with an erythropoietin stimulating agent (ESA) Patient for whom the investigator decided to initiate treatment with Mircera for medical reasons Last hemoglobin level before initiation of Mircera within the range of 1012 g/dL Current participation in a clinical trial on renal anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>